ライフサイエンスコーパス: metanephrine

1 33] vs 10.88 [5.78-18.03] nmol/L; P < .001), metanephrine (0.37 [0.13-1.36] vs 0.12 [0.08-0.28] nmol/

2 Concentrations of UCB metanephrine and 3-methoxytyramine were negatively corre

3 When assayed, urinary metanephrine and catecholamine levels were consistently

4 concentrations of catecholamine metabolites (metanephrine and total metanephrines) and chronic period

5 Plasma-free metanephrines and catecholamines are essential markers i

6 sone suppression test, total 24-hour urinary metanephrines and fractionated catecholamines, and, in t

7 holamine metabolites (metanephrine and total metanephrines) and chronic periodontitis.

8 Concentrations of UCB norepinephrine, metanephrine, and 3-methoxytyramine were negatively corr

9 Concentrations of UCB norepinephrine, metanephrine, and 3-methoxytyramine were positively corr

10 ic resonance imaging, urinary catecholamines/metanephrines, and chromogranin A.

11 ne) and urinary excretion of catecholamines, metanephrines, and vanillylmandelic acid.

12 Measurements of plasma normetanephrine and metanephrine are useful in screening for pheochromocytom

13 were directly correlated to levels of plasma metanephrine but not to normetanephrine.

14 adrenal hyperplasia, plasma epinephrine and metanephrine concentrations and urinary epinephrine excr

15 Plasma epinephrine and metanephrine concentrations and urinary epinephrine excr

16 Comparison of catecholamine and metanephrine concentrations between at-risk neonates and

17 ycemia displayed increased catecholamine and metanephrine concentrations that were correlated with po

18 s including genotype, tumor size, and plasma metanephrines concentrations.

19 d measurements of plasma normetanephrine and metanephrine for detecting pheochromocytomas in patients

20 f measurements of plasma normetanephrine and metanephrine for the detection of tumors was 97 percent,

21 pression test and measurement of plasma-free metanephrines for all patients with an adrenal incidenta

22 inarily high sensitivity of plasma levels of metanephrines for detecting pheochromocytoma have led to

23 plasma and urinary catecholamines and plasma metanephrines in 38 children with congenital adrenal hyp

24 ce intervals for l-DOPA, catecholamines, and metanephrines in n = 115 healthy individuals were establ

25 revious LC-MS/MS method for measuring plasma metanephrines in our laboratory.

26 of unconjugated l-DOPA, catecholamines, and metanephrines in plasma by LC-MS/MS.

27 Urinary total metanephrine levels above the median were associated wit

28 Urinary metanephrine levels above the median were associated wit

29 r MRI findings, or elevated catecholamine or metanephrine levels underwent whole-body planar and sele

30 ology, correlative imaging, catecholamine or metanephrine measurements, and clinical follow-up.

31 Cortisol, creatinine-adjusted cortisol, metanephrine, normetanephrine, and total metanephrines w

32 Urinary metanephrine (P = 0.013) and total metanephrine (P = 0.0

33 Urinary metanephrine (P = 0.013) and total metanephrine (P = 0.023) levels were higher in the case

34 raction LC-MS/MS method for measuring plasma metanephrines (R(2) > 0.99) and high-performance liquid

35 f measurements of plasma normetanephrine and metanephrine was accompanied by a high level of specific

36 plasma concentrations of normetanephrine and metanephrine were compared with the plasma concentration

37 uring and after delivery, catecholamines and metanephrines were analyzed using liquid chromatography

38 Plasma and tissue catecholamines and metanephrines were measured by high-performance liquid c

39 ol, metanephrine, normetanephrine, and total metanephrines were measured in urine.

40 with MEN-2 had high plasma concentrations of metanephrine, whereas the patients with von Hippel-Linda

41 tion of concentrations of catecholamines and metanephrines with the number and severity of postnatal